ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2022
Tumor Sink Effect in
Open access · bronzeAbstract readMulticenter Study
In one paragraph
Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
9.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 76 citations in OpenAlex.
- Clinical Trial Protocol for LPS-Boost: Intensified [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Metformin and renal dosimetry in patients undergoing [European journal of nuclear medicine and molecular imaging · 2026Article
- Influence of increased injected activities up 9.0 GBq [EJNMMI physics · 2026Article
- Biodistribution and dosimetry of the carbon-11 labelled PARP1-selective PET radiopharmaceutical [EJNMMI research · 2026Article
- Multiscale in vivo imaging of tumor evolution using a germline conditional triple-reporter mouse.Nature biotechnology · 2026Article
- Baseline PSMA PET/CT Biomarkers for Patient Selection in [Pharmaceuticals (Basel, Switzerland) · 2026Review
- Long Axial Field-of-view PET: A New Era of Quantitative PET Imaging for Theranostic Applications in Clinic.PET clinics · 2025Review
- PSMA-1-DOTA Potentially for Effective Targeted Radioligand Therapy of Prostate Cancer.Molecular imaging and biology · 2025Article
- Tumor sink effect on melanin-ligand [EJNMMI research · 2025Article
- The tumour sink effect onCancer imaging : the official publication of the International Cancer Imaging Society · 2025Observational
- Evaluation of [18F]PSMA-1007 uptake variability in patients with prostate cancer.Clinical physiology and functional imaging · 2025Article
- Biodistribution and dosimetry of [European journal of nuclear medicine and molecular imaging · 2025Article
- Influence of fasting prior toEJNMMI research · 2024Article
- Prognostic Role of PSMA-Targeted Imaging in Metastatic Castration-Resistant Prostate Cancer: An Overview.Biomedicines · 2024Review
- Superscan Pattern on Bone Scintigraphy: A Comprehensive Review.Diagnostics (Basel, Switzerland) · 2024Review
- Article
- Salivary toxicity from PSMA-targeted radiopharmaceuticals: What we have learned and where we are going.Cancer treatment reviews · 2024Review
- First-in-human study of PSMA-targeting agent, [European journal of nuclear medicine and molecular imaging · 2024Article
- Quantification of biochemical PSA dynamics after radioligand therapy with [EJNMMI physics · 2024Article
- Assessment of PSMA Expression of Healthy Organs in Different Stages of Prostate Cancer Using [Cancers · 2024Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
22 authors at 8 institutions in 3 countries.
Andrei GafitaAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California; agafita@mednet.ucla.edu.
Hui WangDepartment of Nuclear Medicine, Klinikum rechts der Isar, Technical University Munich, Munich, Germany.
Andrew RobertsonDepartment of Nuclear Medicine, Klinikum rechts der Isar, Technical University Munich, Munich, Germany.
Wesley R ArmstrongAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.
Raphael ZaumDepartment of Nuclear Medicine, Klinikum rechts der Isar, Technical University Munich, Munich, Germany.
Manuel WeberDepartment of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium-University Hospital Essen, Essen, Germany.
Farid YagubbayliDepartment of Nuclear Medicine, Klinikum rechts der Isar, Technical University Munich, Munich, Germany.
Clemens KratochwilDepartment of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany.
Tristan R GroganDepartment of Medicine Statistics Core, David Geffen School of Medicine, UCLA, Los Angeles, California.
Kathleen NguyenAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.
Fernando NavarroDepartment of Nuclear Medicine, Klinikum rechts der Isar, Technical University Munich, Munich, Germany.
Rouzbeh EsfandiariExcel Diagnostics and Nuclear Oncology Center, Houston, Texas.
Isabel RauscherDepartment of Nuclear Medicine, Klinikum rechts der Isar, Technical University Munich, Munich, Germany.
Bjoern MenzeDepartment of Informatics, Technical University Munich, Munich, Germany.
David ElashoffDepartment of Medicine Statistics Core, David Geffen School of Medicine, UCLA, Los Angeles, California.
Ebrahim S DelpassandExcel Diagnostics and Nuclear Oncology Center, Houston, Texas.
Ken HerrmannDepartment of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium-University Hospital Essen, Essen, Germany.
Johannes CzerninAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.
Michael S HofmanProstate Cancer Theranostics and Imaging Centre of Excellence, Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.
Jeremie CalaisAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.
Wolfgang P FendlerDepartment of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium-University Hospital Essen, Essen, Germany.
Matthias EiberDepartment of Nuclear Medicine, Klinikum rechts der Isar, Technical University Munich, Munich, Germany.
Klinikum rechts der Isar · DEUniversity of California, Los Angeles · USDeutschen Konsortium für Translationale Krebsforschung · DEExcel Diagnostics Imaging · USTechnical University of Munich · DEEssen University Hospital · DEPeter MacCallum Cancer Centre · AUUniversity Hospital Heidelberg · DE
Funding
Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5MUCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Yvonne Yu-Hsuan Chen · 2017 to 2026
$25.2MNCI NIH HHS P30 CA016042NCI NIH HHS P50 CA211015
Abstract
We aimed to systematically determine the impact of tumor burden on
Indexed as
Gallium RadioisotopesProstatic NeoplasmsEdetic AcidGallium IsotopesHumansMalePositron Emission Tomography Computed TomographyRetrospective StudiesTissue DistributionEdetic Acidgallium 68 PSMA-11Gallium IsotopesGallium RadioisotopesGa-PSMAPETprostate cancerPSMAradioligand therapytumor sink effect
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.